<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064203</url>
  </required_header>
  <id_info>
    <org_study_id>H-17014216</org_study_id>
    <nct_id>NCT04064203</nct_id>
  </id_info>
  <brief_title>The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)</brief_title>
  <official_title>The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to investigate whether hypoglycaemia (the most potent
      stimulus of pancreatic glucagon secretion) affects the secretion of gut-derived glucagon in
      totally pancreatectomized patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators want to assess the plasma glucagon response to insulin-induced
      hypoglycaemia in totally pancreatectomised patients and at the same time evaluate whether
      hypoglycaemia affects a range of other products from endocrine cells in the gastrointestinal
      tract including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic
      polypeptide (GIP), GLP-1, glucagon-like peptide-2 (GLP-2), oxyntomodulin and peptide YY
      (PYY). Furthermore the investigators will evaluate how hypoglycaemia in these patients
      affects other counter-regulatory mechanisms including plasma responses of the hormones
      adrenaline, noradrenaline, growth hormone and cortisol as well as the rate of gastric
      emptying rate (which under normal circumstances accelerates during hypoglycaemia) during an
      oral glucose tolerance test (OGTT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>12 totally pancreatectomized patients and 12 healthy control subjects</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>p-glucagon</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes</time_frame>
    <description>Plasma glucagon excursions measured as incremental area under the curve (iAUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>p-glucose</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes</time_frame>
    <description>plasma glucose excursions measured as incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP, GLP-1, GLP-2, GIP, oxyntomodulin, ghrelin, peptide YY, gastrin</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes</time_frame>
    <description>excursions in Gut hormones measured as incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catecholamines</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes</time_frame>
    <description>p-adrenaline and p-noradrenaline, excursions measured as incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortisol</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes</time_frame>
    <description>p-cortisol excursions measured as incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>growth hormone</measure>
    <time_frame>-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes</time_frame>
    <description>p-growth hormone excursions measured as incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes After Total Pancreatectomy</condition>
  <arm_group>
    <arm_group_label>Totally pancreatectomized patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>50 grams OGTT</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Totally pancreatectomized patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clamp experiment</intervention_name>
    <description>insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Totally pancreatectomized patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pancreatectomised patients

          -  Caucasian above 30 years of age who have undergone total pancreatectomy

          -  Blood haemoglobin &gt;7.0 mmol/l for males and &gt;6.5 mmol/l for females Non-diabetic
             control subjects

          -  Normal fasting plasma glucose and normal HbA1c (according to the World Health
             Organization (WHO) criteria)

          -  Normal blood haemoglobin

          -  Caucasian above 30 years of age

          -  BMI (body mass index) 17-30

          -  Informed consent

        Exclusion Criteria:

        Pancreatectomised patients

          -  Pancreatectomy within the last 3 months

          -  Ongoing chemotherapy or chemotherapy within the last 3 months

          -  Previous or ongoing treatment with GLP-1 receptor agonists or dipeptidyl peptidase 4
             (DPP-4) inhibitors

          -  Inflammatory bowel disease

          -  Gastrointestinal resection (other than the gastro-duodenectomy performed in connection
             with total pancreatectomy) and/or ostomy

          -  Nephropathy (eGFR&lt;60 and/or albuminuria)

          -  Known liver disease (excluding non-alcoholic fatty liver disease) and/or serum alanine
             aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) &gt;3 × normal
             values)

          -  Severe lung disease

          -  Pregnancy and/or breastfeeding

          -  Age above 85 years

          -  Uncontrolled hypertension and/or significant cardiovascular disease

          -  Any condition that the investigator feels would interfere with trial participation
             Non-diabetic control subjects

          -  Diabetes or prediabetes (according to WHO criteria)

          -  First-degree relatives with diabetes

          -  Inflammatory bowel disease

          -  Gastrointestinal resection and/or ostomy

          -  Nephropathy (serum creatinine &gt;150 µmol/l and/or albuminuria)

          -  Known liver disease (excluding non-alcoholic fatty liver disease) and/or serum ALAT
             and/or serum ASAT &gt;3 × normal values)

          -  Severe lung disease

          -  Pregnancy and/or breastfeeding

          -  Age above 85 years

          -  Uncontrolled hypertension and/or significant cardiovascular disease

          -  Any condition that the investigator feels would interfere with trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research</name>
      <address>
        <city>Hellerup</city>
        <state>Capital Region</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Consultant endocrinologist, Professor of</investigator_title>
  </responsible_party>
  <keyword>glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

